MiNK Therapeutics, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $60.8M
- Price
- $12.20
- % Change (Daily % change from the live per-ticker quote feed.)
- +4.99%
- Volume
- 11.8K
About
MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.
Quick stats
Shares outstanding5.0M
Computed float2.0M
Float / shares39.2%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001840229
Websitehttps://minktherapeutics.com
AI Summary
AI-generated1/16
standardbullishearnings
MiNK Therapeutics Reports Second Quarter 2026 Financial Results and Reports Observations from Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury
MiNK reported encouraging initial observations from its randomized Phase 2 trial of agenT-797 in acute lung injury, with the first treated patients alive at Day 28 showing improved oxygenation and reduced inflammation.
Financially, the company narrowed its second quarter net loss to $3.1 million, or $0.62 per share, compared to a loss of $4.2 million, or $1.06 per share, in the prior year period.
The firm also launched a paid named-patient access program in Brazil to enable physician-initiated requests for agenT-797 while generating non-promotional income and establishing international infrastructure.
Red flags
- Cash position of $8.8 million with a quarterly operational burn of $2.1 million suggests a runway of approximately one year
- Clinical observations are preliminary, derived from a small number of patients, and are not yet controlled comparisons from the blinded trial